Drug intelligence / Profile preview

sibirin

Development stage: Preclinical
Lead developer: Goldenrod Therapeutics
Administration: Oral, Inhalation, Intranasal, Intravenous

Overview

Sibirin is an intervention being investigated for the treatment of atypical Benign Paroxysmal Positional Vertigo (BPPV). In a clinical trial, it was administered in an 'Otolith reduction group' alongside earstone reduction. Further details regarding its mechanism of action, developer, or specific pharmaceutical classification are not available from the provided context or general drug databases under this name for this indication.

Other names: sibirin

Targets

NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on sibirin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sibirin.

Explore the full profile